Intuitive Surgical stock gains as Q2 2026 procedures and revenue grow double digit

Intuitive Surgical stock is trading higher as of September 1, 2026, with investors focusing on strong double digit revenue and procedure growth in Q2 2026 and moderated guidance for da Vinci volumes.

Intuitive Surgical stock (ISIN US46120E6023) is trading at about 376.86 dollars on Nasdaq as of September 1, 2026, up around 1.1% from the prior close and keeping the company’s market value firmly in large cap territory according to recent market data.

Strong Q2 2026 figures support the valuation

Recent analysis of Intuitive Surgical’s second quarter 2026 results indicates that revenue for Q2 2026 reached 2.89 billion dollars, an increase of 19% compared with the prior year quarter, underscoring robust growth in the company’s core robotic surgery franchise as reported by a detailed stock overview on August 30, 2026. In the same quarter, worldwide procedures performed on Intuitive’s systems rose about 16% year over year, highlighting continued adoption of minimally invasive surgery using the da Vinci and Ion platforms and reinforcing the recurring nature of instrument, accessory, and service revenue.

The procedure trends in Q1 2026 set the tone for the strong Q2: total procedures across Intuitive Surgical’s platforms grew 17% in Q1 2026, with da Vinci procedures increasing 16% to 847,000 and Ion procedures jumping 39% to 43,000, illustrating how newer platforms like Ion can outpace the mature da Vinci system in growth while still contributing a smaller absolute volume of cases.

Guidance and recent market context

For the full year 2026, Intuitive Surgical has guided for global da Vinci procedure volumes to increase around 13% to 15%, which is slower than the 18% worldwide procedure expansion recorded in fiscal 2025 but still represents solid growth for a company of its scale. Historical context from independent financial analysis shows that Intuitive generated about 10.06 billion dollars in revenue in fiscal 2025, up 21% from roughly 8.35 billion dollars in 2024, with global da Vinci procedures estimated at around 3.15 million in 2025, an increase of about 18% year over year.

The same analysis points out that Intuitive had approximately 11,106 da Vinci systems installed worldwide by the end of 2025, reinforcing the breadth of its installed base and helping explain why recurring instruments and accessories revenue can grow in the high teens even when system placements show more moderate expansion. Intuitive’s guidance for 13% to 15% procedure growth in 2026 therefore signals a deliberate shift from hyper growth toward more measured expansion as the installed base matures and competitive systems from other medical technology companies enter the market.

Market data compiled on August 30, 2026 shows Intuitive Surgical stock closing that day at 372.60 dollars, significantly below its 52 week high of 603.88 dollars, with a trading range between 366.74 and 373.40 dollars suggesting investors are balancing strong recent earnings against concerns about the pace of future growth. Against that backdrop, the September 1, 2026 intraday price of 376.86 dollars implies that the shares are trading nearer the lower half of the recent range, and well below the 603.88 dollar 52 week peak, even as the underlying business continues to deliver double digit revenue and procedure growth.

Analyst consensus and investor perspective

According to a recent institutional holding update, Intuitive Surgical currently carries a consensus rating of Moderate Buy and a consensus price target of 508.68 dollars, indicating that equity analysts on average expect meaningful upside from the current share price level. That same update notes that the stock opened at 376.86 dollars on September 1, 2026, aligning with real time Nasdaq data and reflecting a modest gain of about 1.1% versus the latest prior close.

For investors, the key question is how sustainable the current growth profile will be as Intuitive navigates a more competitive landscape and a maturing installed base. The company’s Q2 2026 revenue growth of 19% year over year, combined with roughly 16% worldwide procedure expansion and full year guidance for 13% to 15% procedure growth, signals that while growth is moderating from the 18% procedure expansion of fiscal 2025, it remains comfortably in double digits; this balance between strong current performance and moderated future expectations appears to be one reason why the shares trade substantially below the 52 week high yet still command a premium valuation.

Da Vinci and Ion platforms in everyday use

Intuitive Surgical’s best known product is the da Vinci robotic surgery system, which is used across a wide range of minimally invasive procedures including urology, gynecology, general surgery, and thoracic operations. By the end of 2025, independent industry research estimated that approximately 11,106 da Vinci systems were installed worldwide, and that the company placed 870 da Vinci 5 systems in 2025, more than double the 362 placed in 2024, demonstrating rapid adoption of the newest generation platform among hospitals and surgeons.

The same research highlighted that worldwide da Vinci procedure volumes rose about 18% in 2025 to roughly 3.15 million procedures, helping drive instruments and accessories revenue growth of 17% to 18%, which is central to Intuitive’s razor and blade business model. In addition to da Vinci, Intuitive’s Ion endoluminal system supports minimally invasive lung biopsy procedures; in Q1 2026, Ion procedures grew 39% year over year to 43,000, compared with 16% growth in da Vinci procedures to 847,000, a pattern that suggests Ion is in a faster growth phase as adoption spreads from early centers to broader clinical use.

Stock price level and investor takeaway

As of September 1, 2026, Intuitive Surgical stock is quoted at about 376.86 dollars on Nasdaq in real time trading, compared with a recent closing price of 372.60 dollars on August 30, 2026 and a 52 week high of 603.88 dollars, placing the shares well below their peak despite sustained double digit revenue and procedure growth. For investors, the combination of Q2 2026 revenue of 2.89 billion dollars, up 19% year over year, worldwide procedure growth of about 16%, and full year guidance for da Vinci procedure volumes to increase 13% to 15% suggests that the current share level embeds both confidence in Intuitive’s da Vinci and Ion platforms and caution about the pace of expansion in a more competitive environment.

Intuitive Surgical key data

• Company: Intuitive Surgical, Inc.
• ISIN: US46120E6023
• Ticker: ISRG
• Trading venue: NASDAQ
• Price (as of September 1, 2026): 376.86 USD
• Market capitalization: 133,000,000,000 USD (as of September 1, 2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: S&P 500